Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Should l Buy BFLY?
Source: NASDAQ.COM
Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.
Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.
Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.
Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.400
Low
4.00
Averages
4.25
High
4.50
Current: 5.400
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Butterfly Network Reports Strong Q1 2026 Earnings with FDA Milestone
- Strong Financial Performance: Butterfly Network reported Q1 2026 revenue of $26.5 million, reflecting a 25% year-over-year growth with a gross margin of 69%, indicating robust growth in both U.S. and international markets, thereby reinforcing its leadership in the point-of-care ultrasound sector.
- Regulatory Milestone: The company achieved FDA clearance for a blind sweep AI tool that can determine fetal age in just two minutes, which is expected to unlock new partnerships with health ministries in developing countries, facilitating business expansion.
- Commercial Plan Update: The company anticipates signing its first commercial agreement for home care in the first half of 2026 and plans to begin training nurses in the third quarter, marking a significant step in its strategy to penetrate the home care market, with expectations for substantial expansion by 2027.
- Growth Drivers: The CFO noted double-digit growth in both core and embedded businesses, with embedded revenue soaring 147% year-over-year, primarily driven by the successful partnership with Midjourney, which is expected to continue enhancing overall company performance.
See More
Butterfly Network Q1 Results Exceed Expectations Despite Stock Drop
- Strong Q1 Performance: Butterfly Network reported Q1 revenue of $26.5 million, a 25% year-over-year increase, yet the stock fell about 8%, indicating investor concerns over ongoing losses.
- Adjusted EBITDA Loss: The company posted an adjusted EBITDA loss of $6.1 million, which, while reduced, failed to bolster investor confidence in future profitability, contributing to downward pressure on the stock.
- Cash Position: At the end of the quarter, Butterfly Network held $138 million in cash, providing a financial cushion for future operations and growth, although market sentiment regarding profitability remains cautious.
- Future Guidance: The company provided Q2 revenue guidance of $27 million to $31 million, aligning with consensus expectations, but lacking upside momentum; however, it reaffirmed its FY26 outlook, indicating steady progress towards profitability.
See More
Butterfly Network Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Butterfly Network reported a Q1 Non-GAAP EPS of -$0.03, beating expectations by $0.02, with revenue reaching $26.5 million, reflecting a robust 25% year-over-year growth that underscores the company's strong market position.
- Adjusted EBITDA Improvement: The adjusted EBITDA loss narrowed to $6.1 million from $9.1 million in the prior year, indicating progress in cost management and operational efficiency, which is crucial for long-term sustainability.
- Cash Position: As of March 31, 2026, Butterfly Network held $138 million in cash and cash equivalents, providing a solid financial cushion that supports ongoing operations and strategic initiatives in the coming months.
- Future Guidance: The company reaffirmed its revenue guidance for FY 2026 at $117 million to $121 million, projecting a 20% to 24% growth, while Q2 revenue is expected to be between $27 million and $31 million, reflecting confidence in market demand.
See More
Butterfly Network Q1 Earnings Preview Scheduled
- Earnings Announcement Date: Butterfly Network (BFLY) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of -$0.05, reflecting a 25% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $25.74 million, representing a 21.4% year-over-year increase, indicating the company's growth potential, particularly driven by embedded partnerships and POCUS growth.
- Historical Performance Review: Over the past two years, BFLY has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating stability in financial performance and market confidence.
- Expectation Revisions: In the last three months, EPS estimates have seen one upward revision with no downward adjustments, while revenue estimates have experienced two upward revisions and no downward changes, reflecting analysts' optimistic outlook on the company's future performance.
See More
Butterfly Network Secures FDA Approval, Stock Surges 90%
- FDA Approval for New Tool: On March 30, Butterfly Network announced it secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestation age in under two minutes, significantly enhancing clinical decision-making efficiency, especially in emergencies or rural settings.
- Massive Market Potential: According to Fortune Business Insights, the global handheld ultrasound market is projected to grow from $397.29 million in 2025 to $1.13 billion by 2034, with Butterfly Network aiming to capture a share of this rapidly expanding market.
- Strong Financial Performance: In Q4 2025, Butterfly reported revenue of $31.5 million, a 41% year-over-year increase that exceeded the consensus estimate of $25.6 million, indicating robust growth potential in the medical imaging device sector.
- Healthy Cash Flow: Butterfly ended 2025 with $150.5 million in cash reserves, enhancing its financial flexibility in market competition and supporting future product development and market expansion.
See More
Butterfly Network Receives FDA Clearance for AI Gestational Age Tool
- FDA Approval: Butterfly Network's fully automated Gestational Age Tool has received FDA clearance, marking it as the first blind-sweep ultrasound AI tool aimed at enhancing the timeliness and accuracy of maternal care globally, which is expected to significantly reduce maternal and fetal mortality rates.
- Technological Innovation: The tool employs deep learning models to deliver reliable gestational age estimates in under two minutes, minimizing user variability and improving decision-making efficiency in emergency settings, particularly in resource-limited areas.
- Global Impact: Already deployed in Malawi and Uganda, the tool aims to improve access to prenatal ultrasound in countries with high maternal and neonatal mortality rates, and FDA clearance will expedite its expansion across Sub-Saharan Africa, supporting global health initiatives.
- Market Potential: With the U.S. federal rural health transformation initiatives underway, the launch of this tool comes at a crucial time, expected to provide easier access to healthcare for pregnant women in remote areas, thereby enhancing overall healthcare accessibility.
See More
Butterfly Network Reports Strong Q1 2026 Earnings with FDA Milestone
- Strong Financial Performance: Butterfly Network reported Q1 2026 revenue of $26.5 million, reflecting a 25% year-over-year growth with a gross margin of 69%, indicating robust growth in both U.S. and international markets, thereby reinforcing its leadership in the point-of-care ultrasound sector.
- Regulatory Milestone: The company achieved FDA clearance for a blind sweep AI tool that can determine fetal age in just two minutes, which is expected to unlock new partnerships with health ministries in developing countries, facilitating business expansion.
- Commercial Plan Update: The company anticipates signing its first commercial agreement for home care in the first half of 2026 and plans to begin training nurses in the third quarter, marking a significant step in its strategy to penetrate the home care market, with expectations for substantial expansion by 2027.
- Growth Drivers: The CFO noted double-digit growth in both core and embedded businesses, with embedded revenue soaring 147% year-over-year, primarily driven by the successful partnership with Midjourney, which is expected to continue enhancing overall company performance.
See More
Butterfly Network Q1 Results Exceed Expectations Despite Stock Drop
- Strong Q1 Performance: Butterfly Network reported Q1 revenue of $26.5 million, a 25% year-over-year increase, yet the stock fell about 8%, indicating investor concerns over ongoing losses.
- Adjusted EBITDA Loss: The company posted an adjusted EBITDA loss of $6.1 million, which, while reduced, failed to bolster investor confidence in future profitability, contributing to downward pressure on the stock.
- Cash Position: At the end of the quarter, Butterfly Network held $138 million in cash, providing a financial cushion for future operations and growth, although market sentiment regarding profitability remains cautious.
- Future Guidance: The company provided Q2 revenue guidance of $27 million to $31 million, aligning with consensus expectations, but lacking upside momentum; however, it reaffirmed its FY26 outlook, indicating steady progress towards profitability.
See More
Butterfly Network Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Butterfly Network reported a Q1 Non-GAAP EPS of -$0.03, beating expectations by $0.02, with revenue reaching $26.5 million, reflecting a robust 25% year-over-year growth that underscores the company's strong market position.
- Adjusted EBITDA Improvement: The adjusted EBITDA loss narrowed to $6.1 million from $9.1 million in the prior year, indicating progress in cost management and operational efficiency, which is crucial for long-term sustainability.
- Cash Position: As of March 31, 2026, Butterfly Network held $138 million in cash and cash equivalents, providing a solid financial cushion that supports ongoing operations and strategic initiatives in the coming months.
- Future Guidance: The company reaffirmed its revenue guidance for FY 2026 at $117 million to $121 million, projecting a 20% to 24% growth, while Q2 revenue is expected to be between $27 million and $31 million, reflecting confidence in market demand.
See More
Butterfly Network Q1 Earnings Preview Scheduled
- Earnings Announcement Date: Butterfly Network (BFLY) is set to announce its Q1 earnings on April 30 before market open, with a consensus EPS estimate of -$0.05, reflecting a 25% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $25.74 million, representing a 21.4% year-over-year increase, indicating the company's growth potential, particularly driven by embedded partnerships and POCUS growth.
- Historical Performance Review: Over the past two years, BFLY has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating stability in financial performance and market confidence.
- Expectation Revisions: In the last three months, EPS estimates have seen one upward revision with no downward adjustments, while revenue estimates have experienced two upward revisions and no downward changes, reflecting analysts' optimistic outlook on the company's future performance.
See More
Butterfly Network Secures FDA Approval, Stock Surges 90%
- FDA Approval for New Tool: On March 30, Butterfly Network announced it secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestation age in under two minutes, significantly enhancing clinical decision-making efficiency, especially in emergencies or rural settings.
- Massive Market Potential: According to Fortune Business Insights, the global handheld ultrasound market is projected to grow from $397.29 million in 2025 to $1.13 billion by 2034, with Butterfly Network aiming to capture a share of this rapidly expanding market.
- Strong Financial Performance: In Q4 2025, Butterfly reported revenue of $31.5 million, a 41% year-over-year increase that exceeded the consensus estimate of $25.6 million, indicating robust growth potential in the medical imaging device sector.
- Healthy Cash Flow: Butterfly ended 2025 with $150.5 million in cash reserves, enhancing its financial flexibility in market competition and supporting future product development and market expansion.
See More
Butterfly Network Receives FDA Clearance for AI Gestational Age Tool
- FDA Approval: Butterfly Network's fully automated Gestational Age Tool has received FDA clearance, marking it as the first blind-sweep ultrasound AI tool aimed at enhancing the timeliness and accuracy of maternal care globally, which is expected to significantly reduce maternal and fetal mortality rates.
- Technological Innovation: The tool employs deep learning models to deliver reliable gestational age estimates in under two minutes, minimizing user variability and improving decision-making efficiency in emergency settings, particularly in resource-limited areas.
- Global Impact: Already deployed in Malawi and Uganda, the tool aims to improve access to prenatal ultrasound in countries with high maternal and neonatal mortality rates, and FDA clearance will expedite its expansion across Sub-Saharan Africa, supporting global health initiatives.
- Market Potential: With the U.S. federal rural health transformation initiatives underway, the launch of this tool comes at a crucial time, expected to provide easier access to healthcare for pregnant women in remote areas, thereby enhancing overall healthcare accessibility.
See More
